Weight Regain After Stopping Semaglutide: What the STEP Trials Reveal

Medically reviewed by Dr. James Whitfield, DO, FACOI

One of the most important questions about semaglutide is what happens when you stop taking it. Data from the STEP 1 extension study and STEP 4 trial reveal that approximately two-thirds of lost weight is regained within one year of discontinuation — reinforcing that obesity requires ongoing treatment.

The Weight Regain Question

Perhaps no question about semaglutide generates more discussion than: "What happens when you stop?" The answer, supported by rigorous clinical trial data, has profound implications for how we understand and treat obesity. Data from the STEP 1 extension study and the STEP 4 trial demonstrate that weight regain after semaglutide discontinuation is substantial — but this finding actually reinforces an important medical principle [1].

STEP 1 Extension: One Year After Stopping

The STEP 1 extension study, published in Diabetes, Obesity and Metabolism in 2022 by Wilding et al., followed participants from the original STEP 1 trial for an additional year after treatment ended [1].

Study Design:

Participants who completed the 68-week STEP 1 trial were followed for an additional 52 weeks off treatment (total 120 weeks)

No semaglutide or placebo was administered during the extension period

Lifestyle counseling continued

Weight Trajectory:

End of treatment (week 68): Semaglutide group had lost -14.9% body weight

One year after stopping (week 120): Semaglutide group had regained weight, with net loss of approximately -5.6% from original baseline

Weight regained: Approximately two-thirds (66%) of the weight lost during treatment was regained within one year of stopping

Cardiometabolic Regression:

The improvements in cardiometabolic parameters also partially reversed:

Waist circumference: Partially regained

Blood pressure: Returned toward baseline

Lipid improvements: Partially lost

CRP (inflammation): Increased back toward pre-treatment levels

HbA1c: Returned toward baseline

However, even one year after stopping, the former semaglutide group still maintained some residual benefit compared to their pre-treatment baseline [1].

---

> Looking for a physician-guided approach? Telegenix connects you with licensed providers who specialize in peptide and testosterone optimization. Every protocol is built on your bloodwork. Learn more and book a consultation.

---

STEP 4: The Withdrawal Design

The STEP 4 trial, published in JAMA in 2021 by Rubino et al., used a clever withdrawal design to specifically study the effects of continuing vs. stopping semaglutide [2].

Study Design:

Run-in phase (weeks 0-20): All 803 participants received semaglutide 2.4 mg (open-label)

Randomization (week 20): Participants who completed run-in were randomized 2:1 to continue semaglutide or switch to placebo for 48 additional weeks

This design isolated the effect of treatment withdrawal after initial weight loss

Results:

During run-in (weeks 0-20): All participants lost approximately -10.6% body weight

Continued semaglutide (weeks 20-68): Further lost to reach -17.4% total weight loss

Switched to placebo (weeks 20-68): Regained weight, ending at -5.0% from original baseline

The Divergence:

Treatment difference at week 68: -12.4 percentage points (P<0.001)

Those who continued semaglutide lost an additional -7.9% body weight

Those who switched to placebo regained +6.9% body weight

The two groups diverged dramatically after randomization, creating a clear "scissors" pattern on the weight trajectory graph [2].

Why Does Weight Regain Occur?

Understanding weight regain requires understanding the biology of obesity:

Metabolic Adaptation:

Weight loss triggers compensatory metabolic changes: reduced resting metabolic rate, increased hunger hormones (ghrelin), and decreased satiety hormones

These adaptations evolved to protect against starvation and persist long after weight loss

Semaglutide counteracts these adaptations while being taken, but the adaptations reassert themselves when the drug is stopped

Neurobiological Reset:

Semaglutide acts on brain appetite centers to reduce hunger and increase satiety

When the drug is removed, the brain's appetite regulation returns to its pre-treatment set point

This is analogous to blood pressure rising when antihypertensive medication is stopped

The Set Point Theory:

The body appears to defend a biological "set point" weight

Semaglutide can shift this set point downward while active

Discontinuation allows the set point to drift back toward its original level [3].

The Chronic Disease Model

The weight regain data has been instrumental in shifting the medical community's understanding of obesity:

Obesity as a Chronic Disease:

Just as hypertension requires ongoing medication, obesity requires ongoing treatment

Stopping semaglutide is analogous to stopping a blood pressure medication — the underlying condition returns

This is not a "failure" of the drug but rather confirmation that obesity is a chronic, relapsing condition

Treatment Duration:

Current evidence supports indefinite treatment for patients who respond to semaglutide

The STEP 5 trial showed sustained efficacy over 2 years with continued treatment

There is no evidence of tolerance (needing higher doses over time) developing

Insurance and Policy Implications:

Weight regain data supports the argument for long-term insurance coverage of anti-obesity medications

Treating obesity as a chronic disease requiring ongoing pharmacotherapy aligns with how we treat other chronic conditions

Strategies to Mitigate Weight Regain

For patients who must discontinue semaglutide, several strategies may help mitigate weight regain:

Gradual dose reduction: Tapering rather than abrupt discontinuation may ease the transition

Intensive lifestyle intervention: Increased focus on diet and exercise during and after discontinuation

Alternative medications: Switching to another weight management medication (e.g., phentermine-topiramate, naltrexone-bupropion) may help maintain some weight loss

Behavioral support: Ongoing counseling and support groups

Metabolic monitoring: Regular monitoring of weight and metabolic parameters to catch early regain

What Patients Should Know

For individuals considering or currently taking semaglutide:

Plan for long-term use: If semaglutide is effective, plan to continue it indefinitely

Weight regain is not your fault: It reflects biology, not willpower

Some benefit persists: Even after stopping, some residual weight loss and metabolic benefit may remain

Discuss with your doctor: Decisions about starting, continuing, or stopping should be made collaboratively with your healthcare provider

> Related Comparison: Ozempic vs Mounjaro: Complete Comparison

References

Wilding JPH, Batterham RL, Davies M, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PubMed: 35441470

Rubino D, Abrahamsson N, Davies M, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA. 2021;325(14):1414-1425. PubMed: 33755728

Bergmann NC, Davies MJ, Lingvay I, Knop FK. "Semaglutide for the treatment of overweight and obesity: A review." Diabetes, Obesity and Metabolism. 2023;25(1):18-35. PMC: 10092086

---

> Want to explore this therapy under medical supervision? Telegenix offers telehealth consultations with providers who specialize in peptides and hormone optimization. Book your free consultation today.

---